5 Results for "

Colon 38

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Colon 38" in MCE Product Catalog:

Cat. No.: HY-103001
CAS No.: 173528-92-2
Purity:  97.21%
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

HMN-154 is a novel benzenesulfonamide anticancer compound; inhibits KB and colon38 cells with IC50 values of 0.0026 and 0.003 μg/mL, respectively.
loading...
    loading...
Cat. No.: HY-P2045
CAS No.: 86229-97-2
Target:  

Arp2/3 Complex

Research Areas:  

Cancer

RA-VII is an antitumor agent that exhibits significant activity against L1210, B-16 melanoma, Lewis lung carcinoma, Colon 38 and Ehrlich carcinoma .
loading...
    loading...
Cat. No.: HY-118385
CAS No.: 247186-96-5
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

ER-67880 is a potent microtubule inhibitor with an IC50 of 9.5 μM. ER-67880 exhibits anti-proliferative activity against KB, Colon 38 and P338 cells with IC50s of 0.55, 0.2 and 0.76 μg/mL. ER-67880 causes G2/M phase arrest and is accompanied by abnormal DNA replication. ER-67880 exhibits a down-regulation pattern of G1 phase-related genes. ER-67880 can be used in various cancer studies, including those of nasopharyngeal carcinoma and murine adenocarcinoma .
loading...
    loading...
Cat. No.: HY-103001R
CAS No.: 173528-92-2
Research Areas:  

Cancer

HMN-154 (Standard) is the analytical standard of HMN-154 (HY-103001). This product is intended for research and analytical applications. HMN-154 is a novel benzenesulfonamide anticancer compound; inhibits KB and colon38 cells with IC50 values of 0.0026 and 0.003 μg/mL, respectively.
loading...
    loading...
Cat. No.: HY-159803
CAS No.: 128201-92-3
Synonyms: 6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin
Target:  

Endogenous Metabolite

Research Areas:  

Cancer

IST-622 (6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin) is an anti-tumor agent with significant growth inhibitory activity. IST-622 exhibits significant anti-tumor effects against a variety of mouse tumors such as P388 and L1210 leukemias, B16 melanoma, Lewis lung carcinoma, Colon 26 and Colon 38 adenocarcinomas, and M5076 reticulum cell sarcoma. IST-622 was orally administered and the results showed efficacy in different tumor types. In addition, IST-622 provided significant inhibitory effects against two human tumor xenograft models: large cell lung carcinoma (Lu-116) and gastric adenocarcinoma (St-4). IST-622 also exhibited significant growth inhibitory activity against P388 leukemia in vitro, with a half inhibitory concentration (IC50) more than 20 times lower than CT .
loading...
    loading...